SCORE2 Comparative Trial

Grants and Contracts Details


The Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) will assess whether one of the most commonly used anti-VEGF drgus, bevacizumab, is non-inferior to a second generation anti-VEGF drug, aflibercept, for the treatment of macular edema secondary to Central Retinal Vein Occlusion. Rescue therapy, in cases where intial therapy is not successful, will be evaluated.
Effective start/end date9/30/133/31/19


  • The Pennsylvania State University: $19,494.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.